MSOS stock forecast, quote, news & analysis

Key Takeaways

• MSOS gained roughly +18% over the trailing 30 days, recovering from about $4.21 to near $4.97 per share.
• The advance is a sharp rebound from a mid-summer pullback; over the trailing three months the fund is essentially flat (approximately -1.6%).
• Federal rescheduling of medical cannabis to Schedule III, and the resulting Section 280E tax relief, is the dominant catalyst.
• Trulieve's historic NYSE listing and a broadly stronger-than-expected Q2 2026 earnings season for U.S. multi-state operators (MSOs) fueled investor sentiment.
• Renewed consolidation, including Curaleaf's takeover bid for Aurora Cannabis, added momentum to the sector.

AdvisorShares Pure US Cannabis ETF (MSOS) Overview and Portfolio Exposure

The AdvisorShares Pure US Cannabis ETF is an actively managed, non-diversified fund that seeks long-term capital appreciation by investing at least 80% of its net assets in U.S. companies deriving at least 50% of revenue from the marijuana and hemp business, along with derivatives with similar economic characteristics. The fund holds roughly 112 portfolio positions, including swap contracts and cash collateral, and carries a net expense ratio of approximately 0.78%.

Because plant-touching U.S. cannabis operators were long barred from major domestic exchanges under federal prohibition, the fund historically built much of its exposure through total return swaps, which explains its sizable cash and Treasury collateral balances. The portfolio is highly concentrated in multi-state operators, with the largest exposures to Curaleaf Holdings, Trulieve Cannabis (TRLV), and Green Thumb Industries, alongside Verano, Cresco Labs, Glass House Brands, and TerrAscend.

This structure concentrates the fund's performance in a small number of U.S. operators whose fortunes hinge on state-level program growth, profitability, and the pace of federal reform — which is precisely why regulatory headlines and earnings reports drive outsized swings in the fund's share price.

AdvisorShares Pure US Cannabis ETF (MSOS) Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, MSOS climbed approximately +18%, rising from a close near $4.21 to roughly $4.97 per share. The move was not a smooth grind higher; it was a rebound-driven recovery characterized by elevated volume and pronounced daily volatility, including a sharp rally in late August.

The broader three-month picture tells a different story. From a level near $5.05 about three months earlier, the fund finished roughly -1.6% lower, effectively flat on the period. This flat result masks a turbulent round trip: a spring-to-early-summer advance, a mid-summer drawdown as regulatory optimism faded, and the subsequent recovery that drove the recent 30-day gain. In short, the latest move is best understood as a re-rating off a local bottom rather than a fresh all-time breakout.

What Drove MSOS Price in the Last 30 Days

The primary driver was federal reform. Medical cannabis was reclassified to Schedule III of the Controlled Substances Act, unlocking Section 280E relief — the tax provision that previously disallowed ordinary business deductions for cannabis companies — and directly improving the cash flow and tax profiles of the fund's medical-focused operators.

Trulieve's listing on the New York Stock Exchange under TRLV — the first U.S. cannabis operator on a major domestic exchange — marked a sector milestone and lifted sentiment across the space. The company completed its Delaware domestication and reported adjusted earnings of $0.11 per share, beating estimates, while raising full-year operating cash flow guidance to at least $225 million and announcing a share repurchase program.

Earnings were broadly constructive across the portfolio. Curaleaf swung to net income of about $12.5 million on $340 million in revenue, Green Thumb Industries posted $307 million in revenue with $84 million in normalized EBITDA, Cresco Labs reported $173 million in revenue, and Verano generated $218 million in revenue with $51 million in adjusted EBITDA. A wave of M&A — highlighted by Curaleaf's roughly $260 million takeover bid for Aurora Cannabis — reinforced the perception that stronger operators are positioned to consolidate a recovering industry.

What Drove MSOS Performance Over the Last Quarter

The trailing quarter reflects a full cycle of sentiment around the rescheduling timeline. An initial burst of optimism in the spring gave way to a summer pullback as investors recognized that medical-only rescheduling leaves adult-use cannabis in Schedule I and that broader reform would take time to materialize. Positioning and profit-taking amplified the drawdown.

The recovery that followed was anchored in fundamentals rather than headlines alone: improving profitability, tax relief beginning to flow through to margins, and the first exchange uplisting all signaled that the sector's balance-sheet repair is translating into market access and investor interest. Because MSOS is concentrated in a handful of these operators, their collective re-rating drove the fund's rebound over the final stretch of the quarter.

AI Screener

Investors seeking to identify securities moving on regulatory and earnings catalysts can use Tickeron's AI Screener, an AI-powered stock and ETF discovery platform that scans thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. The tool helps investors surface trending securities, breakout candidates, and fresh trading opportunities more efficiently than manual screening, making it a practical complement to a fundamentals-driven review of thematic ETFs like MSOS. Explore the platform to refine your own watchlist and discovery process.

MSOS ETF Outlook: What Investors Should Watch Next

The most consequential variable remains the DEA's pending decision on adult-use rescheduling, following the conclusion of its broader hearings. A shift for adult-use cannabis would materially expand tax relief and cash-flow benefits beyond medical operators, while a delay could test the recent rally.

Investors should also monitor further exchange uplistings, the pace of 280E-related tax savings, and state-level program expansion in markets such as Georgia, Texas, and Florida. Banking reform and capital-markets access remain structural overhangs, while M&A consolidation and disciplined share repurchases signal management confidence but also introduce execution risk. Given the fund's concentration in a handful of operators and its history of high volatility, regulatory headlines, earnings cycles, and capital flows will continue to dominate its near-term direction.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations